The global montelukast sodium market size was estimated to be USD 0.451 billion in 2023 and is predicted to reach USD 2.24 billion by 2034 with a CAGR of 15.71% during the forecast period 2024-2034. Increased geriatric population, growing awareness of the benefits of Montelukast sodium, growing R&D investments, a greater emphasis on preventative healthcare, rising prevalence of respiratory diseases, and strategic partnerships and collaborations will significantly boost the market's growth.
The increased prevalence of respiratory ailments including allergic rhinitis and asthma has greatly fueled the market for montelukast sodium. As a leukotriene receptor antagonist, montelukast reduces inflammation and bronchoconstriction to successfully treat asthma symptoms. When used for allergic rhinitis, it relieves symptoms such as itching, sneezing, and congestion of the nose. For instance, the US Food and Drug Administration (FDA) authorized Sun Pharmaceutical Industries Ltd. to sell its generic montelukast sodium tablets in the US in May 2022. It is anticipated that this clearance will lead to more competition and lower prices in the US market.
By product type, the montelukast sodium amorphous segment accounted for the highest revenue-grossing segment in the global montelukast sodium market in 2023 owing to the superior bioavailability and increased solubility compared to crystalline forms. These innovative formulations have enhanced the drug's efficacy, leading to higher patient compliance and therapeutic outcomes, driving significant market adoption. For instance, Mylan N.V. introduced a new generic montelukast sodium oral disintegrating tablet in the US market in April 2021. The new tablet is easier for those who have trouble swallowing to take because of its rapid dissolution in the mouth. Additionally, the montelukast sodium crystalline segment is predicted to grow at the fastest CAGR during the forecast period owing to the increased focus on long-term stability and scalability in pharmaceutical manufacturing.
By dosage form, the tablets segment accounted for the highest revenue-grossing segment in the global montelukast sodium market in 2023 owing to the convenience of administration and widespread patient acceptance. For instance, Cipla Limited introduced a new chewable montelukast sodium tablet in India in February 2023. The updated tablet is meant to be easier for kids to use. Additionally, the oral solutions segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for alternative dosage forms and increased focus on patient-centric drug delivery.
By application, the asthma segment accounted for the highest revenue-grossing segment in the global montelukast sodium market in 2023 owing to the prevailing high prevalence of asthma worldwide and the effectiveness of Montelukast Sodium in managing asthma symptoms. For instance, montelukast sodium was added to the World Health Organization's (WHO) Essential Medicines List in August 2023, demonstrating the drug's significance in the treatment of asthma and allergic rhinitis around the world. Additionally, the allergic rhinitis segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness, diagnosis, and prevalence of allergic rhinitis, coupled with the efficacy of Montelukast Sodium in managing allergic symptoms.
By distribution channel, the retail pharmacies segment accounted for the highest revenue-grossing segment in the global montelukast sodium market in 2023 owing to the extensive accessibility and ease of medication distribution to a broad patient population. For instance, Glenmark Pharmaceuticals Ltd. introduced a new sugar-free version of its montelukast sodium tablets in India in February 2024 to accommodate diabetic patients or those wishing to avoid added sugar. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of e-commerce platforms, the convenience of online purchasing, and a growing trend towards digital healthcare solutions.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of respiratory conditions, well-established healthcare infrastructure, and robust adoption of Montelukast Sodium in the management of asthma and allergic disorders. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising awareness of respiratory diseases, increasing healthcare infrastructure development, and a growing patient population. For instance, the European Medicines Agency (EMA) started reviewing the safety profile of montelukast sodium in December 2023 in response to reports of possible neuropsychiatric adverse effects.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
The increased prevalence of respiratory ailments including allergic rhinitis and asthma has greatly fueled the market for montelukast sodium. As a leukotriene receptor antagonist, montelukast reduces inflammation and bronchoconstriction to successfully treat asthma symptoms. When used for allergic rhinitis, it relieves symptoms such as itching, sneezing, and congestion of the nose. For instance, the US Food and Drug Administration (FDA) authorized Sun Pharmaceutical Industries Ltd. to sell its generic montelukast sodium tablets in the US in May 2022. It is anticipated that this clearance will lead to more competition and lower prices in the US market.
By product type, the montelukast sodium amorphous segment accounted for the highest revenue-grossing segment in the global montelukast sodium market in 2023 owing to the superior bioavailability and increased solubility compared to crystalline forms. These innovative formulations have enhanced the drug's efficacy, leading to higher patient compliance and therapeutic outcomes, driving significant market adoption. For instance, Mylan N.V. introduced a new generic montelukast sodium oral disintegrating tablet in the US market in April 2021. The new tablet is easier for those who have trouble swallowing to take because of its rapid dissolution in the mouth. Additionally, the montelukast sodium crystalline segment is predicted to grow at the fastest CAGR during the forecast period owing to the increased focus on long-term stability and scalability in pharmaceutical manufacturing.
By dosage form, the tablets segment accounted for the highest revenue-grossing segment in the global montelukast sodium market in 2023 owing to the convenience of administration and widespread patient acceptance. For instance, Cipla Limited introduced a new chewable montelukast sodium tablet in India in February 2023. The updated tablet is meant to be easier for kids to use. Additionally, the oral solutions segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for alternative dosage forms and increased focus on patient-centric drug delivery.
By application, the asthma segment accounted for the highest revenue-grossing segment in the global montelukast sodium market in 2023 owing to the prevailing high prevalence of asthma worldwide and the effectiveness of Montelukast Sodium in managing asthma symptoms. For instance, montelukast sodium was added to the World Health Organization's (WHO) Essential Medicines List in August 2023, demonstrating the drug's significance in the treatment of asthma and allergic rhinitis around the world. Additionally, the allergic rhinitis segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness, diagnosis, and prevalence of allergic rhinitis, coupled with the efficacy of Montelukast Sodium in managing allergic symptoms.
By distribution channel, the retail pharmacies segment accounted for the highest revenue-grossing segment in the global montelukast sodium market in 2023 owing to the extensive accessibility and ease of medication distribution to a broad patient population. For instance, Glenmark Pharmaceuticals Ltd. introduced a new sugar-free version of its montelukast sodium tablets in India in February 2024 to accommodate diabetic patients or those wishing to avoid added sugar. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of e-commerce platforms, the convenience of online purchasing, and a growing trend towards digital healthcare solutions.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of respiratory conditions, well-established healthcare infrastructure, and robust adoption of Montelukast Sodium in the management of asthma and allergic disorders. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising awareness of respiratory diseases, increasing healthcare infrastructure development, and a growing patient population. For instance, the European Medicines Agency (EMA) started reviewing the safety profile of montelukast sodium in December 2023 in response to reports of possible neuropsychiatric adverse effects.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
Study Coverage
- Market Forecast by Product Type, Dosage Form, Application, and Distribution channel
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Montelukast Sodium Market Report 2023 - 2034
Montelukast Sodium Market Analysis & Forecast by Product Type 2023 - 2034 (Revenue USD Bn)
- Montelukast Sodium Amorphous
- Montelukast Sodium Crystalline
Montelukast Sodium Market Analysis & Forecast by Dosage Form 2023 - 2034 (Revenue USD Bn)
- Tablets
- Oral Solutions
Montelukast Sodium Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Asthma
- Allergic Rhinitis
- Urticaria
- Other Applications
Montelukast Sodium Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Montelukast Sodium Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Montelukast Sodium Market: Product Type Estimates & Trend Analysis
8. Montelukast Sodium Market: Dosage Form Estimates & Trend Analysis
9. Montelukast Sodium Market: Application Estimates & Trend Analysis
10. Montelukast Sodium Market: Distribution Channel Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Montelukast Sodium Market
13. Europe Montelukast Sodium Market
14. Asia Pacific Montelukast Sodium Market
15. Latin America Montelukast Sodium Market
16. MEA Montelukast Sodium Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Merck & Co. Inc.
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Aurobindo Pharma Limited
- Dr. Reddy's Laboratories Ltd.
- Cipla Limited
- Sandoz International GmbH (Novartis)
- Jubilant Life Sciences Ltd.
- Glenmark Pharmaceuticals Ltd.
- Lupin Limited
- Sun Pharmaceutical Industries Ltd.
- Apotex Inc.
- Torrent Pharmaceuticals Ltd.
- Zydus Cadila.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 0.45 Billion |
| Forecasted Market Value ( USD | $ 2.24 Billion |
| Compound Annual Growth Rate | 15.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
